
ãã¡ã€ã¶ãŒç€Ÿã®æ©å¯ææžã«ãããCOVIDã¯ã¯ãã³ãæ¥çš®ããåŠå©Šã®82-97%ã詊éšäžã«æ²ããããšã«èµ€ã¡ããã倱ã£ãããšã確èªãããã
å èšäºã¯ãã¡ã/Original article here
FDAãè£å€æåœä»€ã«ãã£ãŠå
¬è¡šãäœåãªãããããã¡ã€ã¶ãŒã®æ©å¯ææžã«ããã°ã誀ã£ãŠmRNAã³ããã19泚å°ãåãã女æ§ã®82ïŒ
ãã97ïŒ
ãæµç£ããããåºç£æã«æ°çå
ã®æ»ãç®æãã矜ç®ã«é¥ã£ãããšãæããã«ãªã£ãŠããã
ãããããã¡ã€ã¶ãŒç€Ÿã¯ãããããã®åŠåš äžã®äœ¿çšäŸã®æ€èšãããå®å
šæ§ã®ã·ã°ãã«ã¯åºãŠããªãããšèåœã®äž»åŒµãããŠããã

ç±³é£åå»è¬åå±ïŒFDAïŒã¯ã2020幎12æ11æ¥ã«ããã108æ¥éã®å®å šæ§å¯©æ»ã§æ³šå°ãæ¿èªããã«ããããããããã¡ã€ã¶ãŒã®COVID-19ã¯ã¯ãã³ã®å®å šæ§ããŒã¿ã®å ¬éã75幎éé ãããããšããŸããã
ãããã2022幎1æåæ¬ãé£éŠå€äºããŒã¯ã»ããããã³ã¯ãæ¯æ55,000ããŒãžãå ¬éããããåœããã1ææ«ãŸã§ã«12,000ããŒãžãå ¬éããã®ã§ãã
ãã以æ¥ãPHMPTã¯ãã¹ãŠã®ææžããŠã§ããµã€ãã«æ²èŒããŠãããææ°ã®æäžã¯ã2022幎8æ1æ¥ã«èµ·ãã£ãã
ããŒã¿ãã³ãã«å«ãŸããææžã®1ã€ããreissue_5.3.6 postmarketing experience.pdfãã§ããããã®æ©å¯ææžã®12ããŒãžã«ã¯ããã¡ã€ã¶ãŒç€Ÿã®ã³ãã19泚å°å€ã®åŠåš äžããã³æä¹³äžã®äœ¿çšã«é¢ããããŒã¿ãèšèŒãããŠããã
ãã¡ã€ã¶ãŒã¯ãã®ææžã®äžã§ã2021幎2æ28æ¥ãŸã§ã«ãåŠåš äžã«mRNA泚å°å€ã«æé²ãããæ¢ç¥ã®çäŸã¯270ä»¶ã§ãããšäž»åŒµããŠããã

ãã®ãã¡146äŸã®æ¯èŠªã¯ãèšåºçæå®³äºè±¡ã®çºçãçŽã¡ã«å ±åããªãã£ãããããã270äººã®æ¯èŠªã®ãã¡124人ã¯å ±åããŠãããã€ãŸãããã¡ã€ã¶ãŒç€Ÿã®ã³ããã19泚å°å€ã«æé²ãããæ¯èŠªã®46ïŒ ãå¯äœçšã被ã£ãããšã«ãªãã
ãã®124åã®ãã¡49åã¯éé節ãªå¯äœçšã§ãã£ããã75åã¯é節ãªå¯äœçšãšããããã€ãŸããå¯äœçšã蚎ããæ¯èŠªã®58ïŒ ããåå®®åçž®ããèå æ»äº¡ãŸã§ã®éç¯€ãªæå®³äºè±¡ã«èŠèãããããšã«ãªãã

ãã¡ã€ã¶ãŒç€Ÿè£œæ³šå°å€ã®æé²ã«ãããåèš 4 ä»¶ã®é節ãªèå ã»ä¹³å ã®çäŸãå ±åãããŸããããã®4ä»¶ã®é節ãªã±ãŒã¹ã¯ã以äžã®äºè±¡ãå«ãã§ããŸãã
èå çºè²äžå š x2
æ©ç£å x2
æ°çå æ»äº¡ x1

ãããããããããããªãåé¡ã§ããããã¡ã€ã¶ãŒç€Ÿã¯ã270ä»¶ã®åŠåš ã®ãã¡ã238ä»¶ã«äœãèµ·ãã£ãã®ãå šãåãããªããšçºè¡šããŠããã

ããããæ®ãã®åŠåš ã®çµæã倿ããŠããã®ã¯ä»¥äžã®éãã§ãã
èªç¶æµç£(æµç£)x23ã
çµæä¿çÃ5ã
æ°çå æ»äº¡ãäŒŽãæªçå x2,
åå®®å èå æ»äº¡ã䌎ãèªç¶æµç£Ã2ã
æ°çå æ»äº¡ã䌎ãèªç¶æµç£Ã1
æ£åžžãªçµæ x1


å ±åæžã®æç¹ã§ã¯34ä»¶ã®è»¢åž°ããã£ããããã®ãã¡5ä»¶ã¯ãŸã æªè§£æ±ºã§ãã£ãããã¡ã€ã¶ãŒç€Ÿã¯ã29ã®æ¢ç¥ã®çµæã®ãã¡æ£åžžãªãã®ã¯1ã€ã ãã§ããã28ã®çµæã¯èµ€ã¡ããã®æå€±/æ»äº¡ã«ã€ãªãã£ããšææããŠãããããã¯ãåŠåš äžã®Covid-19ã¯ã¯ãã³æ¥çš®ã®æ¢ç¥ã®çµæã®97ïŒ ãåäŸã®æ»äº¡ã«ã€ãªãã£ãããšã«çžåœããã
çµæãæªç¢ºå®ã®5ä»¶ãå«ãããšãåŠåš äžã®Covid-19ã¯ã¯ãã³æ¥çš®ã®å šçµæã®ãã¡82ïŒ ãåã©ãã®æ»äº¡ã«ã€ãªãã£ãããšã«ãªããŸããã€ãŸãã82ïŒ ãš97ïŒ ã®éã®å¹³åå€ã¯çŽ90ïŒ ãšããããšã«ãªããŸãã
ãããããã®82ïŒ ãšããæ°åã¯ãçŸç 管çã»ã³ã¿ãŒV-Safe COVID-19åŠåš ç»é²ããŒã ãè¡ã£ãå¥ã®ç ç©¶ã®çµæãèãããšãéåžžã«è峿·±ããã®ã§ããè±åœã§ã³ãã19泚å°ãåããããåŠå©Šã«å§ããã ãã§ãªããå«ããããããããšãæ£åœåããããã«äœ¿ããã調æ»ã§ãã
ç§ãã¡ã¯2021幎7æãã³ããã-19ã¯ã¯ãã³ãåŠåš äžã«äœ¿çšããŠãå®å šã§ããããšã瀺ãããã«ãCDCã®ããã®å®äžç調æ»ã宿œããŠããç§åŠè ã«ãã£ãŠããŒã¿ãã©ã®ããã«æäœãããŠããããç¬å çã«æããã«ããŸããã
èè ãã¯ãç ç©¶äžã«èªç¶æµç£ïŒæµç£ïŒãããäººã®æ°ã¯ãå®äºãã827ä»¶ã®åŠåš ã®ãã¡104ä»¶ã§ãæµç£ã®ãªã¹ã¯ã¯12.6%ã§ãããäžè¬éå£ã«ãããæµç£ã®ãªã¹ã¯ãã7ïœ12%äœããšäž»åŒµããŸããã

ããããæã ã®åæã«ãããšãåŠåš ãå®äºãã827人ã®ãã¡ã700人ïŒ86ïŒ ïŒã®å¥³æ§ãåŠåš 第3æã«ãã¡ã€ã¶ãŒãŸãã¯ã¢ããã®Covid-19ã¯ã¯ãã³ãæ¥çš®ããŠãããåŠåš 20é±ä»¥åã«ããæµç£ãèµ·ãããªãããããã®æ°åã¯æ¥µããŠèª€è§£ãæããããããšã蚌æãããŸããã
ã€ãŸããåŠåš 第1æïŒç¬¬2æã«ãã¡ã€ã¶ãŒç€ŸãŸãã¯ã¢ãã«ã瀟ã®Covid-19ã¯ã¯ãã³ãæ¥çš®ãã女æ§ã¯ããã127人ã§ããã®ãã¡104äººãæ®å¿µãªããèµ€ã¡ããã倱ã£ãŠããŸã£ãã®ã§ãã
ãããã£ãŠãæµç£ã®çºççã¯82ïŒ ã§ãããç ç©¶çµæã«ç€ºããã12.6ïŒ ã§ã¯ãªãã£ãããã®ç ç©¶ã®èè ã¯ãã®åŸãèªåãã¡ã®èª€ããèªãããã®ç ç©¶ãäžçäžã®åŠå©Šãæ°ããæ¯èŠªã«å¯Ÿããã³ããã-19ã¯ã¯ãã³æ¥çš®ã®æ£åœåã«å©çšãããããã6ã¶æé ãã§èšæ£ãçºè¡šããã®ã§ããã

ãããããã®82ïŒ ãšããæ°åããŸãåºãŠããããã¡ã€ã¶ãŒã®æ©å¯ããŒã¿ãš CDCã®æäœãããç ç©¶ã®2ã€ã®ããŒã¿ã§ ã³ããã19ã¯ã¯ãã³æ¥çš®åŸã®åŠåš åªå€±çã82%ãšããããšã§ããåãªãå¶ç¶ã®äžèŽãïŒ
å»çèŠå¶åœå±ãšãã¡ã€ã¶ãŒç€Ÿãé èœããããšããããšãèãããšããã®å¯èœæ§ã¯æ¥µããŠäœãã
ãã¡ã€ã¶ãŒç€Ÿã®ã³ããã19泚å°ã«é¢ããå¯äžã®åŠåš ïŒäžåŠç ç©¶ã詳现ã«èª¿æ»ãããæ å ±å ¬éãè«æ±ã«ããããã¡ã€ã¶ãŒç€Ÿãšå»çèŠå¶åœå±ããåŠåš äžã®ã³ããã19ã¯ã¯ãã³æ¥çš®ã®å±éºæ§ãé ããŠããããšãæããã«ãªã£ãã
調æ»ã®å šæã¯ããã§èªãããšãã§ããããããã§ã¯å ¬åŒã®å ¬çææžã«å«ãŸããã¹ãã§ããããã®åŸå«ãŸããªãã£ããã®ã®æç²ã玹ä»ããã

FDAããã¡ã€ã¶ãŒã®ããŒã¿ã«å¯Ÿå¿ããªãããšã決å®ãããã¡ã€ã¶ãŒãšäžçäžã®å»çèŠå¶åœå±ãåç©å®éšçµæãé èœããããšã«ããã2022幎4æ22æ¥çŸåšãã³ããã19泚å°å€ã®å¯äœçšãšããŠç±³åœã ãã§4,113人ã®èå æ»äº¡ãå ±åãããŠããŸãã

ãããŠãã¹ã³ããã©ã³ãã§çºè¡šããããã®ããŒã¿ãèŠãŠãã ããã

ã¹ã³ããã©ã³ãå ¬è¡è¡çå±ïŒPHSïŒã¯ãCovid-19ã®å»çå¶åºŠãžã®ããåºã圱é¿ã«é¢ããå®å šãªããã·ã¥ããŒããããã«æ²èŒããŠããã粟ç¥è¡ççµ±èšããåŠåš ãå¿è¡ç®¡é害ããŒã¿ãçãŸã§ããããããŒã¿ãå«ãŸããŠããŸãã
å ¬åŒã®æ°åã«ãããšã2022幎3æã®æ°çå æ»äº¡çã¯åºç1000人ããã4.6人ã«å¢å ããäºæ³æ»äº¡çã«å¯ŸããŠ119ïŒ ã®å¢å ãšãªã£ãŠããŸããããã¯ãæ°çå æ»äº¡çãå°ãªããšã4幎ã¶ã2åç®ã«ã管çéçããšåŒã°ããèŠåã®äžéãçªç Žããããšãæå³ããã
ååçªç Žããã®ã¯2021幎9æã§ããã®ãšãã¯åºç1000人åœããã®æ°çå æ»äº¡æ°ã5.1ãŸã§äžæãããæã«ãã£ãŠå€åã¯ãããã®ã®ã2021幎9æãš2022幎3æã®æ°å€ã¯ã1980幎代åŸåã«æåŸã«å žåçã«èŠãããæ°ŽæºãšåçšåºŠã§ããã
ã¹ã³ããã©ã³ãå ¬è¡è¡çå±ïŒPHSïŒã¯èª¿æ»ãéå§ããããšãæ£åŒã«çºè¡šããŠããªãããããã¯èŠåã®äžéå€ã«éãããšãã«è¡ãããšã«ãªã£ãŠããã2021å¹Žåœæã¯ããããŠããã
åœæPHSã¯ã管çäžéå€ãè¶ ãããšããããšã¯ããçºçããæ»è ã®æ°ã«ãã©ã³ãã ãªå€å以äžã®èŠå ãããå¯èœæ§ãé«ãããšã瀺ããŠããããšè¿°ã¹ãŠããŸãã詳ããã¯ãã¡ãã§ã芧ããã ããŸãã
æã ã¯ããã§æ·±å»ãªåé¡ãæ±ããŠããããæãããå¶ç¶ã®ç©ã¿éãã®ã©ã¡ããã§ããããããŠãåŠåš äžã«èª€ã£ãŠã³ããã19泚å°ãåãã女æ§ã®82ïŒ ãã97ïŒ ãåäŸã倱ã£ãããšã«å¯ŸããŠããã¡ã€ã¶ãŒç€Ÿãæ©å¯ææžã§è¡ã£ããã®ä¿¡ãããã䞻匵ã®ãããã§ãã¹ãŠãçããã®ã§ããã
"ãããã®åŠåš äžã»æä¹³äžã®äœ¿çšäŸã®æ€èšããæµ®ãã³äžãã£ãå®å šæ§ã®ã·ã°ãã«ã¯ãããŸããã§ããã"

ãã¡ãã®æ©å¯ææžã®12ããŒãžãš13ããŒãžã§ã確èªãã ããã